CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers.
作者信息
Markert C, Burhenne J, Weiss J, Mikus G, Haefeli W E
机构信息
Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany.
出版信息
Clin Pharmacol Ther. 2014 Mar;95(3):250-1. doi: 10.1038/clpt.2013.188. Epub 2013 Sep 18.
PMID:24048276
Abstract
摘要
Zotero 插件